Compare · HSDT vs MDT
HSDT vs MDT
Side-by-side comparison of Solana Company (HSDT) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSDT and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $116.83B, about 1177.0x HSDT ($99.3M).
- Over the past year, HSDT is down 70.7% and MDT is down 1.9% - MDT leads by 68.8 points.
- MDT has been more active in the news (14 items in the past 4 weeks vs 5 for HSDT).
- MDT has more recent analyst coverage (25 ratings vs 3 for HSDT).
- Company
- Solana Company
- Medtronic plc.
- Price
- $1.73-3.35%
- $91.25+0.75%
- Market cap
- $99.3M
- $116.83B
- 1M return
- +1.76%
- +9.24%
- 1Y return
- -70.73%
- -1.89%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 14
- Recent ratings
- 3
- 25
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest HSDT
- SEC Form 10-Q filed by Solana Company
- Solana Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solana Company Reports Second Quarter 2026 Financial Results
- Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026
- SEC Form 4 filed by CEO and President Chee Choon Wee
- New insider Summer Wisdom Holdings Ltd claimed ownership of 6,830,402 shares (SEC Form 3)
- Large owner Summer Wisdom Holdings Ltd disposed of 1,453,277 shares (SEC Form 4)
- Solana Company Partners with Alatau City to Advance Digital Asset Infrastructure and Blockchain Adoption in Central Asia
- Solana Company Board Unanimously Rejects Unsolicited Forward Industries Proposal
- Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)
Latest MDT
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 212 units of Ordinary Shares and was granted 2,337 units of Ordinary Shares, increasing direct ownership by 14% to 16,998 units (SEC Form 4)
- EVP & President, Neuroscience Thompson Kweli covered exercise/tax liability with 1,739 units of Ordinary Shares and was granted 6,923 units of Ordinary Shares, increasing direct ownership by 17% to 35,390 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 1,675 units of Ordinary Shares and was granted 5,769 units of Ordinary Shares, increasing direct ownership by 11% to 39,928 units (SEC Form 4)
- EVP, GC and Secretary Quinn Michelle was granted 6,346 units of Ordinary Shares, increasing direct ownership by 31% to 26,721 units (SEC Form 4)
- EVP & Chief Financial Officer Pieton Thierry was granted 11,537 units of Ordinary Shares, increasing direct ownership by 30% to 49,645 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael was granted 57,107 units of Ordinary Shares and covered exercise/tax liability with 3,356 units of Ordinary Shares, increasing direct ownership by 84% to 117,420 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 3,074 units of Ordinary Shares and was granted 9,230 units of Ordinary Shares, increasing direct ownership by 16% to 43,669 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey was granted 41,533 units of Ordinary Shares and covered exercise/tax liability with 15,810 units of Ordinary Shares, increasing direct ownership by 9% to 327,866 units (SEC Form 4)